Hepatobiliary Pharmaceutical Holdings Limited (Hepubao Medicine - B) submitted a new next-day disclosure report on September 25, 2024, disclosing its shareholding changes. According to the report, on September 25, 2024, the company repurchased 157,000 ordinary shares at a repurchase price ranging from HKD 1.17 to HKD 1.24 per share, totaling approximately HKD 189,590. After the repurchase, the company's issued shares decreased to 767,465,410 shares, while treasury shares increased to 1,411,000 shares. The share repurchase has been formally authorized and approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. The company confirms that the repurchased shares will be held as treasury shares, with no plans for any new share issuance or resale or transfer of treasury shares until October 25, 2024.

Hepatobiliary Pharmaceutical Holdings Limited (Hepubao Medicine - B) submitted a new next-day disclosure report on September 25, 2024, disclosing its shareholding changes. According to the report, on September 25, 2024, the company repurchased 157,000 ordinary shares at a repurchase price ranging from HKD 1.17 to HKD 1.24 per share, totaling approximately HKD 189,590. After the repurchase, the company's issued shares decreased to 767,465,410 shares, while treasury shares increased to 1,411,000 shares. The share repurchase has been formally authorized and approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. The company confirms that the repurchased shares will be held as treasury shares, with no plans for any new share issuance or resale or transfer of treasury shares until October 25, 2024.